文献速递临床试验与 GCP

半剂量与稳定剂量传统合成改善病情抗风湿药对类风湿关节炎缓解期患者疾病复发的影响:ARCTIC REWIND随机临床试验

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

ARCTIC REWIND研究纳入160例持续缓解12个月的类风湿关节炎患者,随机接受半剂量或稳定剂量csDMARD治疗,随访12个月。半剂量组复发率25%,稳定剂量组6%,风险差异18%(95%CI 7%-29%),未达到非劣效界值20%。结论不支持对缓解期患者采用半剂量csDMARD治疗。

要点

  • 持续缓解的RA患者减半csDMARD剂量后12个月复发风险显著高于维持稳定剂量。
  • 半剂量组复发率25%,稳定剂量组6%,风险差异18%(95%CI 7%-29%)。
  • 半剂量未达到预设的20%非劣效界值,不支持减量策略。

核心结论

  • 在持续缓解的RA患者中,半剂量csDMARD相比稳定剂量未达到非劣效性,稳定剂量组复发显著更少。

研究设计与样本

  • 多中心、随机、平行、开放标签非劣效性研究,在挪威10家医院风湿科开展。
  • 纳入160例持续缓解12个月且接受稳定csDMARD治疗的RA患者,随机分为半剂量组(n=80)和稳定剂量组(n=80)。
  • 主要终点为基线至12个月随访期间疾病复发的患者比例,非劣效界值为风险差异20%。

主要发现

  • 半剂量组19例(25%)发生复发,稳定剂量组5例(6%)发生复发,风险差异18%(95%CI 7%-29%)。
  • 半剂量组34例(44%)发生不良事件,稳定剂量组42例(54%)发生不良事件,均未导致研究终止。
  • 无死亡病例报告。

关键数值与推荐

  • 复发定义:DAS>1.6且DAS评分增加≥0.6分且至少2个关节肿胀,或患者与研究者共同认为发生临床显著复发。
  • 非劣效界值为风险差异20%。

临床怎么用

  • 对于持续缓解的RA患者,不应常规将csDMARD减至半剂量,维持稳定剂量可降低复发风险。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小,随访期12个月,长期结果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains unclear. OBJECTIVE: To assess the effect of tapering of csDMARDs, compared with continuing csDMARDs without tapering, on the risk of flares in patients with RA in sustained remission. DESIGN, SETTING, AND PARTICIPANTS: ARCTIC REWIND was a multicenter, randomized, parallel, open-label noninferiority study conducted in 10 Norwegian hospital-based rheumatology practices. A total of 160 patients with RA in remission for 12 months who were receiving stable csDMARD therapy were enrolled between June 2013 and June 2018, and the final visit occurred in June 2019. INTERVENTIONS: Patients were randomly assigned to half-dose csDMARDs (n = 80) or stable-dose csDMARDs (n = 80). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients with a disease flare between baseline and the 12-month follow-up, defined as a combination of Disease Activity Score (DAS) greater than 1.6 (threshold for RA remission), an increase in DAS score of 0.6 units or more, and at least 2 swollen joints. A disease flare could also be recorded if both the patient and investigator agreed that a clinically significant flare had occurred. A risk difference of 20% was defined as the noninferiority margin. RESULTS: Of 160 enrolled patients (mean [SD] age, 55.1 [11.9] years; 66% female), 156 received the allocated therapy, of which 155 without any major protocol violations were included in the primary analysis population (77 receiving half-dose and 78 receiving stable-dose csDMARDs). Flare occurred in 19 patients (25%) in the half-dose csDMARD group compared with 5 (6%) in the stable-dose csDMARD group (risk difference, 18% [95% CI, 7%-29%]). Adverse events occurred in 34 patients (44%) in the half-dose group and 42 (54%) in the stable-dose group, none leading to study discontinuation. No deaths occurred. CONCLUSIONS AND RELEVANCE: Among patients with RA in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs did not demonstrate noninferiority for the percentage of patients with disease flares over 12 months, and there were significantly fewer flares in the stable-dose group. These findings do not support treatment with half-dose therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01881308.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. JAMA. 2021. PMID: 33944875. doi:10.1001/jama.2021.4542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。